SAN DIEGO: SAN DIEGO, Dec. 14, 2021 /PRNewswire/ — Arthrosi Therapeutics, Inc., a clinical-stage biotech company announced today patient enrollment in a global phase 2b study of AR882, its novel drug candidate. AR882 is a new uricosuric agent in clinical development for the management of hyperuricemia in patients with gout, including patients with chronic, refractory tophaceous gout. Arthrosi Therapeutics, Inc. announced today patient enrollment in a global phase 2b study of AR882
Click here to view original post
Copyright © 2023 Biotech Networks, LLC
